Item 1.01. Entry into a Material Definitive Agreement.
On February 13, 2019, CytoDyn Inc. (the
Company
) entered into Subscription Agreements (the
Subscription Agreements
)
with certain investors (the
Investors
) for the sale by the Company of 1,320,000 shares (the
Common Shares
) of the Companys common stock, par value $0.001 per share (the
Common Stock
), in
a registered direct offering (the
Offering
). The Investors in the Offering also received warrants to purchase 660,000 shares of Common Stock (the
Warrants
). Each share of Common Stock was sold together with one
half of one Warrant to purchase one share of Common Stock for a combined purchase price of $0.50.
The aggregate gross proceeds for the sale of the Common
Shares and Warrants will be approximately $0.7 million. Subject to certain ownership limitations, the Warrants will be exercisable commencing on the issuance date at an exercise price equal to $0.50 per share of Common Stock, subject to
adjustments as provided under the terms of the Warrants. The Warrants are exercisable for five years from the date of issuance. The closing of the sales of these securities under the Subscription Agreements is expected to occur on or about
February 13, 2019.
The net proceeds to the Company from the transactions, after deducting the fees and expenses of the Placement Agent, as defined
below (not including the Placement Agent Warrants, as defined below), the Companys estimated offering expenses, and excluding the proceeds, if any, from the exercise of the Warrants, are expected to be approximately $0.6 million. The
Company intends to use the net proceeds from the transactions to fund clinical trials for its lead product candidate and for general corporate purposes.
The securities sold in the Offering were offered and sold by the Company pursuant to an effective shelf registration statement on
Form S-3,
which was initially filed with the Securities and Exchange Commission (the
SEC
) on February 23, 2018 and subsequently declared effective on March 7, 2018 (File
No. 333-223195)
(the
Registration Statement
), and the base prospectus dated as of March 7, 2018 contained therein. The Company will file a prospectus supplement with the SEC in
connection with the sale of the securities.
The representations, warranties and covenants contained in the Subscription Agreements were made solely for
the benefit of the parties to the Subscription Agreements. In addition, such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Subscription Agreements and not as statements of
fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company. Accordingly, the forms of the Subscription Agreements are included with
this filing only to provide investors with information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company. Stockholders should not rely on the representations, warranties and
covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties
may change after the date of the Subscription Agreements, which subsequent information may or may not be fully reflected in public disclosures.
Pursuant
to the Placement Agent Agreement, dated as of December 31, 2018 (the
Placement Agent Agreement
) with Paulson Investment Company, LLC (the
Placement Agent
), the Company has agreed to pay the Placement Agent
a cash fee equal to 9% of the gross proceeds received by the Company from investors in the Offering, as well as a
one-time
non-accountable
expense fee of $35,000 for
aggregate expenses incurred collectively in the Offering (which was previously paid in connection with a prior closing). Pursuant to the Placement Agent Agreement, the Company also agreed to grant to the Placement Agent or its designees warrants to
purchase up to 9% of the aggregate number of shares sold to investors in the Offering at an exercise price of $0.50 per share (the
Placement Agent Warrants
). The Placement Agent Warrants provide for cashless exercise. The
Placement Agent Agreement has indemnity and other customary provisions for transactions of this nature. The Placement Agent Warrants and the shares issuable upon exercise of the Placement Agent Warrants will be issued in reliance on the exemption
from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws. The Placement Agent Agreement was filed as Exhibit 10.2
to the Form 8-K filed on January 31, 2019 and is incorporated herein by reference.
The forms of Warrant and Subscription Agreement are filed as Exhibits
4.1 and 10.1, respectively, to the Form 8-K filed on January 31, 2019. The foregoing summaries of the terms of these documents are subject to, and qualified in their entirety by, such documents, which are incorporated herein by reference.
The legal opinion and consent of Lowenstein Sandler LLP relating to the securities are filed as Exhibit 5.1 to this Current Report on
Form 8-K.